Back to search results

Observational Study of Lung Cancer Surgery After Chemo-immunotherapy

This study is looking back at the medical records of people who had surgery for non-small cell lung cancer (NSCLC) between 2016 and 2024. These patients first received a treatment called neoadjuvant chemo-immunotherapy (chemotherapy combined with immunotherapy) or immunotherapy alone. The study wants to compare different types of lung surgery – robotic, VATS (video-assisted thoracoscopic surgery, a minimally invasive approach), and open surgery – to see which one had fewer complications in the 30 to 90 days after the operation. This will help doctors understand the best surgical approach for patients who have already received these treatments. You might be eligible if you are an adult (18 or older) with stage IIB or III NSCLC who had one of these surgeries after neoadjuvant chemo-immunotherapy.

Study design
This is an observational study looking at past medical records of 140 patients. It is not testing a new treatment but rather comparing existing surgical methods.
What's involved
There are no risks for patients because this study only collects information from existing medical records. You would not need to do anything extra.
Compensation
Not stated in the trial record.
Follow-up
The study looks at complications occurring 30 to 90 days after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06626243

Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers

Recruiting
Not specifiedAges 18+Observational
Scientific Institute San Raffaele
~140 participants
Updated 2024-11-29 on ClinicalTrials.gov

At a glance

Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The perioperative complication of video-assisted thoracoscopic surgery (VATS) approach
Measured over 30-90 days after surgery
+2 more outcomes measured

Conditions

Non-Small Cell Lung Cancer

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

6 sites across 5 states
Italy2
Florida1
New York1
West Virginia1
Milan1

Who to contact

Pierluigi Novellis, Medical Doctor
[email protected]
0226437202 · ext. +39
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of clinical or pathological stage IIB (T1-2, hilar N1, M0) and III (any T, N1-2, M0) NSCLC surgically treated with robotic, VATS and open approach with radical intent from 1st of January 2016 to 31st of March 2024
Received neoadjuvant chemo-immunotherapy or immunotherapy alone
Age \>= 18 years old at the moment of surgery

Exclusion

Age \<18 years old at the moment of surgery

What this trial measures

  • The perioperative complication of video-assisted thoracoscopic surgery (VATS) approach30-90 days after surgery

    The investigators will measure the perioperative complications of VATS approach in patients who received neoadjuvant chemo-immunotherapy. Complications will be categorized according to the Clavien-Dindo scale.

  • The perioperative complications of robotic approachfrom the surgery at 30-90 days after

    The investigators will measure the perioperative complications of robotic lung resection in patients who received neoadjuvant chemo-immunotherapy. Complications will be categorized according to the Clavien-Dindo scale.

  • The perioperative complications of the open approach30-90 days after surgery

    The investigators will measure the perioperative complications of open approach in patients who received neoadjuvant chemo-immunotherapy. Complications will be categorized according to the Clavien-Dindo scale.